{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohorting&page=58", "query": { "intervention": "Cohorting", "page": 58 }, "page_size": 10 }, "pagination": { "page": 58, "page_size": 10, "total_count": 11367, "total_pages": 1137, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohorting&page=59&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohorting&page=57&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-29T10:08:13.076Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06100887", "title": "Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Duchenne Muscular Dystrophy" ], "interventions": [ { "name": "Sevasemten Dose 1", "type": "DRUG" }, { "name": "Sevasemten Dose 2", "type": "DRUG" }, { "name": "Sevasemten Dose 3", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Edgewise Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "17 Years", "sex": "MALE", "summary": "6 Years to 17 Years · Male only" }, "enrollment_count": 43, "start_date": "2024-03-22", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2025-11-06", "last_synced_at": "2026-10-29T10:08:13.076Z", "location_count": 7, "location_summary": "Los Angeles, California • Sacramento, California • Gainesville, Florida + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Worcester", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06100887" }, { "nct_id": "NCT05567393", "title": "A Study of TAK-951 in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "TAK-951 Placebo", "type": "DRUG" }, { "name": "TAK-951", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 128, "start_date": "2019-03-07", "completion_date": "2020-11-02", "has_results": true, "last_update_posted_date": "2023-09-14", "last_synced_at": "2026-10-29T10:08:13.076Z", "location_count": 1, "location_summary": "Glendale, California", "locations": [ { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05567393" }, { "nct_id": "NCT07871214", "title": "A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Early-Stage Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Pumitamig", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2026-11-30", "completion_date": "2028-03-15", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-29T10:08:13.076Z", "location_count": 9, "location_summary": "Long Beach, California • Los Angeles, California • Tampa, Florida + 6 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chestnut Hill", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07871214" }, { "nct_id": "NCT05581004", "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced or Metastatic Solid Tumors", "NSCLC", "HNSCC", "Melanoma", "TNBC", "Esophageal Cancer", "Gastric Cancer", "Cervical Cancer", "Colorectal Cancer", "Urothelial Carcinoma", "Clear Cell RCC", "HCC" ], "interventions": [ { "name": "Enzelkitug", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 165, "start_date": "2022-10-20", "completion_date": "2028-07-31", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-10-29T10:08:13.076Z", "location_count": 10, "location_summary": "San Francisco, California • Aurora, Colorado • Sarasota, Florida + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05581004" }, { "nct_id": "NCT02608385", "title": "Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "Stereotactic body radiotherapy (SBRT)", "type": "RADIATION" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 117, "start_date": "2015-12", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2025-06-08", "last_synced_at": "2026-10-29T10:08:13.076Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02608385" }, { "nct_id": "NCT00844285", "title": "SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "Cimzia", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB BIOSCIENCES, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3072, "start_date": "2009-01-30", "completion_date": "2020-08-21", "has_results": true, "last_update_posted_date": "2023-05-06", "last_synced_at": "2026-10-29T10:08:13.076Z", "location_count": 197, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 157 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00844285" }, { "nct_id": "NCT06563804", "title": "A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)", "Myelodysplastic Syndrome (MDS)/AML", "Chronic Myelomonocytic Leukemia (CMML)" ], "interventions": [ { "name": "S227928", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Servier Bio-Innovation LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2025-02-25", "completion_date": "2025-10-09", "has_results": false, "last_update_posted_date": "2026-03-30", "last_synced_at": "2026-10-29T10:08:13.076Z", "location_count": 5, "location_summary": "Duarte, California • Fairway, Kansas • Grand Rapids, Michigan + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Fairway", "state": "Kansas" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06563804" }, { "nct_id": "NCT05925049", "title": "A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Natalizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 400, "start_date": "2023-06-30", "completion_date": "2026-10-31", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-10-29T10:08:13.076Z", "location_count": 1, "location_summary": "Cambridge, Massachusetts", "locations": [ { "city": "Cambridge", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05925049" }, { "nct_id": "NCT04430738", "title": "Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Carcinoma", "Gastric Adenocarcinoma", "GEJ Adenocarcinoma", "Esophageal Adenocarcinoma", "Cholangiocarcinoma", "Gallbladder Carcinoma" ], "interventions": [ { "name": "tucatinib", "type": "DRUG" }, { "name": "trastuzumab", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "leucovorin", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2020-09-15", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-10-29T10:08:13.076Z", "location_count": 21, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04430738" }, { "nct_id": "NCT04234048", "title": "Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "T-cell Lymphoma", "Cutaneous/Peripheral T-Cell Lymphoma", "Peripheral T-cell Lymphoma", "Peripheral T-Cell Lymphoma, Not Classified", "Primary Cutaneous T-cell Lymphoma", "Cutaneous T-Cell Lymphoma, Unspecified", "Cutaneous T-cell Lymphoma", "Follicular T-Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Sézary's Disease", "Mycosis Fungoides" ], "interventions": [ { "name": "Fenretinide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SciTech Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2023-12-18", "completion_date": "2028-11-01", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-29T10:08:13.076Z", "location_count": 10, "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04234048" } ] }